Clene Inc.
CLNNNasdaq
$5.92
↑ +4.0%Jul 17 close · end-of-day
Price
1Y↑ +57.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$134,000.00
Net Income (TTM)
-$33.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-15722.4%
Net Margin
-25009.7%
ROE
178.2%
ROIC
—
Debt / Equity
-0.9
Net Cash
-$11.8M
Return 1Y
+51.8%
Company profile
Clene Inc. focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis. The company also markets and distributes dietary supplements.
- CEO
- Robert D. Etherington
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- Utah
- Website
- clene.com
Earnings
CLNN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$15,000.00↓ -81.5%
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $206,000.00 | $723,000.00 | $473,000.00 | $654,000.00 | $342,000.00 | $200,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$20.2M | -$50.0M | -$48.4M | -$40.5M | -$33.1M | -$23.1M |
| Net income | -$19.3M | -$9.7M | -$29.9M | -$49.5M | -$39.4M | -$26.2M |
| Diluted EPS | — | — | — | — | — | — |
| Operating cash flow | -$18.9M | -$34.6M | -$39.0M | -$30.2M | -$21.3M | -$18.5M |
| Free cash flow | -$19.3M | -$36.0M | -$44.2M | -$30.5M | -$21.3M | -$18.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -9812.6% | -6912.6% | -10234.5% | -6198.8% | -9676.3% | -11541.5% |
| Net margin | -9357.8% | -1347.2% | -6325.2% | -7569.4% | -11520.5% | -13086.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $91,000.00 | $87,000.00 | $91,000.00 | $81,000.00 | $27,000.00 | $15,000.00 | $77,000.00 | $15,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$7.4M | -$7.8M | -$8.7M | -$4.1M | -$5.9M | -$5.6M | -$7.5M | -$2.1M |
| Net income | -$6.8M | -$8.0M | -$13.5M | -$751,000.00 | -$7.4M | -$8.8M | -$9.2M | -$8.1M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$6.4M | -$3.0M | -$4.9M | -$5.0M | -$4.7M | -$4.0M | -$4.8M | -$4.5M |
| Free cash flow | -$6.4M | -$3.0M | -$4.9M | -$5.0M | -$4.7M | -$4.0M | -$4.8M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -8122.0% | -8982.8% | -9511.0% | -5032.1% | -21718.5% | -37653.3% | -9733.8% | -13740.0% |
| Net margin | -7456.0% | -9179.3% | -14889.0% | -927.2% | -27477.8% | -58513.3% | -11981.8% | -53940.0% |
Company news
Jun 4, 2026
May 22, 2026
May 19, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-04 | Ugwumba Chidozie | Sale | 72,884 | $6.80 | $495,611.20 | filing |
| 2026-05-01 | Ugwumba Chidozie | Sale | 5,795 | $6.01 | $34,827.95 | filing |
| 2026-04-30 | Ugwumba Chidozie | Sale | 5,736 | $6.08 | $34,874.88 | filing |
| 2026-04-29 | Ugwumba Chidozie | Sale | 12,170 | $5.63 | $68,517.10 | filing |
| 2026-04-28 | Ugwumba Chidozie | Sale | 1,591 | $5.90 | $9,386.90 | filing |
| 2026-04-21 | Ugwumba Chidozie | Sale | 61,345 | $6.14 | $376,658.30 | filing |
| 2026-04-20 | Ugwumba Chidozie | Sale | 4,318 | $6.12 | $26,426.16 | filing |
| 2026-04-17 | Ugwumba Chidozie | Sale | 25,040 | $6.43 | $161,007.20 | filing |
| 2026-04-16 | Ugwumba Chidozie | Sale | 7,748 | $6.40 | $49,587.20 | filing |
| 2026-04-15 | Ugwumba Chidozie | Sale | 6,374 | $6.48 | $41,303.52 | filing |
| 2026-04-02 | Ugwumba Chidozie | Sale | 24,925 | $4.81 | $119,889.25 | filing |
| 2026-04-01 | Ugwumba Chidozie | Sale | 4,278 | $4.97 | $21,261.66 | filing |
| 2026-03-31 | Ugwumba Chidozie | Sale | 67,991 | $4.88 | $331,796.08 | filing |
| 2026-03-30 | Ugwumba Chidozie | Sale | 15,536 | $5.10 | $79,233.60 | filing |
| 2026-03-27 | Ugwumba Chidozie | Sale | 17,470 | $4.75 | $82,982.50 | filing |
| 2026-03-26 | Ugwumba Chidozie | Sale | 5,319 | $5.40 | $28,722.60 | filing |
| 2026-03-25 | Ugwumba Chidozie | Sale | 7,098 | $5.50 | $39,039.00 | filing |
| 2026-03-24 | Ugwumba Chidozie | Sale | 5,492 | $5.78 | $31,743.76 | filing |
| 2026-02-03 | Ugwumba Chidozie | Sale | 5,559 | $4.10 | $22,791.90 | filing |
| 2026-02-02 | Ugwumba Chidozie | Sale | 3,800 | $4.04 | $15,352.00 | filing |
| 2026-01-30 | Ugwumba Chidozie | Sale | 5,686 | $4.13 | $23,483.18 | filing |
| 2026-01-29 | Ugwumba Chidozie | Sale | 15,284 | $4.32 | $66,026.88 | filing |
| 2026-01-28 | Ugwumba Chidozie | Sale | 8,717 | $4.91 | $42,800.47 | filing |
| 2026-01-27 | Ugwumba Chidozie | Sale | 4,139 | $5.08 | $21,026.12 | filing |
| 2026-01-26 | Ugwumba Chidozie | Sale | 6,418 | $5.02 | $32,218.36 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.